---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-035953"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T07:40:32.996496+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aldeyra R&D Day: reproxalap NDA resubmission H2 2024; positive preclinical data for ADX-246, ADX-629

## Summary
- Reproxalap NDA resubmission expected H2 2024, pending Phase 3 dry eye chamber trial results and FDA discussions.
- ADX-629 showed statistically significant improvement in EASI, itching, and POEM scores in Phase 2 atopic dermatitis trial.
- ADX-246 reduced hepatic acetaldehyde, histopathology, and liver enzymes in preclinical alcoholic hepatitis model.
- ADX-629 enhanced GLP-1-mediated weight and fat mass loss in a diet-induced obesity mouse model.
- Next-generation RASP modulators ADX-248 and ADX-246 demonstrated broad activity in preclinical inflammation models.

## SEC filing metadata
- accession: 0001213900-24-035953
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000121390024035953/0001213900-24-035953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000121390024035953/ea0204620-8k_aldey.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-035953
- JSON: https://secwatch.observer/filing/0001213900-24-035953.json
- Plain text: https://secwatch.observer/filing/0001213900-24-035953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.